CN107207442A - 新的芳基‑氰基胍化合物 - Google Patents

新的芳基‑氰基胍化合物 Download PDF

Info

Publication number
CN107207442A
CN107207442A CN201580075621.9A CN201580075621A CN107207442A CN 107207442 A CN107207442 A CN 107207442A CN 201580075621 A CN201580075621 A CN 201580075621A CN 107207442 A CN107207442 A CN 107207442A
Authority
CN
China
Prior art keywords
dihydro
pyrazol
cyano
phenyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580075621.9A
Other languages
English (en)
Chinese (zh)
Inventor
J·S·莫瓦特
T·斯特菲尔德
C·斯特莱斯曼
R·休利格
S·科尔
D·斯托凯特
J·威斯克
T·布伦比
N·巴勒
C·克莱斯特
A·特尔拉克
V·巴道克
R·H·克兰普顿
I·斯特法努缇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN107207442A publication Critical patent/CN107207442A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580075621.9A 2014-12-08 2015-12-08 新的芳基‑氰基胍化合物 Pending CN107207442A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14196766 2014-12-08
EP14196766.1 2014-12-08
EP15163993 2015-04-17
EP15163993.7 2015-04-17
PCT/EP2015/078912 WO2016091845A1 (en) 2014-12-08 2015-12-08 Novel aryl-cyanoguanidine compounds

Publications (1)

Publication Number Publication Date
CN107207442A true CN107207442A (zh) 2017-09-26

Family

ID=54838348

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580075621.9A Pending CN107207442A (zh) 2014-12-08 2015-12-08 新的芳基‑氰基胍化合物

Country Status (7)

Country Link
US (1) US10023539B2 (enExample)
EP (1) EP3230274B1 (enExample)
JP (1) JP2017538697A (enExample)
CN (1) CN107207442A (enExample)
CA (1) CA2969771A1 (enExample)
ES (1) ES2722431T3 (enExample)
WO (1) WO2016091845A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111270394A (zh) * 2019-02-18 2020-06-12 宜春希宇生物制品有限公司 一种抗菌面料及其制备方法
CN116327748A (zh) * 2023-04-21 2023-06-27 武汉科技大学 联合用药物在制备抗肿瘤药物中的用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3700904B1 (en) 2017-10-24 2023-07-19 Bayer AG 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
CA3137610A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
EP3959211A1 (en) 2019-04-24 2022-03-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
CA3137611A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
CA3177214A1 (en) 2020-03-31 2021-10-07 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
CN115998869B (zh) * 2022-09-23 2025-08-05 华中科技大学同济医学院附属同济医院 组蛋白甲基转移酶smyd2在制备防治血管损伤后内膜新生导致再狭窄的药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007157A1 (de) * 2003-07-15 2005-01-27 Bayer Healthcare Ag Pyrazoline als par-1-antagonisten zur behandlung von herz-kreislauf-erkrankungen
WO2006072349A1 (de) * 2004-12-22 2006-07-13 Bayer Healthcare Ag Thiophen-substituierte pyrazoline
WO2006072350A1 (de) * 2004-12-22 2006-07-13 Bayer Healthcare Ag Cyanoguanidin-substituierte pyrazoline
CN103261160A (zh) * 2010-09-03 2013-08-21 福马Tm有限责任公司 用于抑制nampt的胍化合物和组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503696A (ja) 1990-01-31 1993-06-17 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 殺節足動物性ピラゾリン類、ピラゾリジン類およびヒドラジン類
DE102004061748A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Azetidin-substituierte Pyrazoline

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007157A1 (de) * 2003-07-15 2005-01-27 Bayer Healthcare Ag Pyrazoline als par-1-antagonisten zur behandlung von herz-kreislauf-erkrankungen
WO2006072349A1 (de) * 2004-12-22 2006-07-13 Bayer Healthcare Ag Thiophen-substituierte pyrazoline
WO2006072350A1 (de) * 2004-12-22 2006-07-13 Bayer Healthcare Ag Cyanoguanidin-substituierte pyrazoline
CN103261160A (zh) * 2010-09-03 2013-08-21 福马Tm有限责任公司 用于抑制nampt的胍化合物和组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDREW D. FERGUSON等: "Structural Basis of Substrate Methylation and Inhibition of SMYD2", 《STRUCTURE》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111270394A (zh) * 2019-02-18 2020-06-12 宜春希宇生物制品有限公司 一种抗菌面料及其制备方法
CN116327748A (zh) * 2023-04-21 2023-06-27 武汉科技大学 联合用药物在制备抗肿瘤药物中的用途

Also Published As

Publication number Publication date
WO2016091845A1 (en) 2016-06-16
JP2017538697A (ja) 2017-12-28
ES2722431T3 (es) 2019-08-12
US20170342034A1 (en) 2017-11-30
US10023539B2 (en) 2018-07-17
EP3230274B1 (en) 2019-01-30
CA2969771A1 (en) 2016-06-16
EP3230274A1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
EP3700904B1 (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
EP3458443B1 (en) Aromatic sulfonamide derivatives
CN107207442A (zh) 新的芳基‑氰基胍化合物
JP6704398B2 (ja) ４Ｈ−ピロロ［３，２−ｃ］ピリジン−４−オン誘導体
EP3532474B1 (en) 4,5-annulated 1,2,4-triazolones
EP3921317B1 (en) 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
US20240307362A1 (en) 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS
US12403135B2 (en) 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CA3095233A1 (en) 4-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disorders
CN115485030A (zh) 咪唑并三嗪通过抑制cdk12作用于癌症
WO2018104307A1 (en) Aromatic sulfonamide derivatives and their use as anatagon i sts or negative allosteric modulators of p2x4
WO2020126968A2 (en) Urea derivatives
EP4188928A1 (en) Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof
US20180118722A1 (en) Novel aryl-cyanoguanidine compounds
CN118541372A (zh) 用于治疗癌症的双环三嗪衍生物
US20180099937A1 (en) Novel aryl-cyanoguanidine compounds
US11161825B2 (en) 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamides
WO2024028316A1 (en) 1h-pyrrolo[3,2-b]pyridine derivatives as irreversible inhibitors of mutant egfr for the treatment of cancer
HK40085534A (en) Imidazotriazines acting on cancer via inhibition of cdk12
HK1262908B (en) Aromatic sulfonamide derivatives
HK1262908A1 (en) Aromatic sulfonamide derivatives
EA040608B1 (ru) Ароматические сульфонамидные производные

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170926